American Association for Cancer Research

Continuing Medical Education (CME)

ACCREDITATION STATEMENT

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council of Continuing Medical Education (ACCME) to provide continuing medical education (CME) activities for physicians.


CREDIT DESIGNATION STATEMENT

The AACR has designated this educational activity for a maximum of 35.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE, AND LEARNING OBJECTIVES

Advances in technology, progress in prevention, and exponential developments in the field of translational cancer medicine lead to rapid changes in oncology practice. By bridging the gap between what physicians understand about cancer biology and the clinical applications, this meeting aids basic researchers, physicians, and clinician-scientists in obtaining, synthesizing, and integrating the most cutting-edge research. This exposure is essential for the implementation of best practices, such as the most current molecular-based tests to aid in the diagnosis, treatment, and prevention of cancer. Further, facilitating the interface between physicians and scientists will increase knowledge of the epidemiological implications of cancer incidence and the contributions of laboratory research to drug development as well as patient care; transform the design and conduct of clinical research protocols; and create a forum for the rapid translation of laboratory research findings from “bench-to-bedside” for the benefit of improving patient outcomes.

    After participating in this CME activity, participants will be able to:
  1. Employ technological advances to accelerate progress in cancer research and improve early detection and early intervention, with the ultimate goal of extending patients’ lives and improving their quality of life;
  2. Integrate molecular assays and screening techniques to determine cancer susceptibility and predict lifetime risk;
  3. Integrate the use of molecular imaging and tumor profiling to more accurately develop treatment strategies;
  4. Improve patient selection (or stratification) for clinical trials through the use of biomarkers and other indicators;
  5. Synthesize the latest research findings regarding therapies and treatment options in a variety of cancer types in order to refine patient treatment;
  6. Utilize models for cancer survivorship and the latest information on childhood/adolescent exposures to help predict lifetime cancer risk and long-term outcomes for adult survivors of childhood cancer;
  7. Interpret the role of epigenetics in cancer etiology and its potential for development of novel therapeutics;
  8. Distinguish the role of the immune system in fighting and promoting tumor development; and
  9. Evaluate the role of targeted therapies so that they can be optimized for patients with metastatic disease.

DISCLOSURE STATEMENT

It is the policy of the AACR that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that Program Committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. In addition, off-label and investigational uses were identified at the time of presentation. As part of AACR's policy on full disclosure of relevant financial relationships, the disclosure information is available by clicking the link below:

QUESTIONS ABOUT CME?

Please contact the AACR Office of CME at (215) 440-9300 or cme@aacr.org.